Cereno Scientific will attend at BIO-Europe 2018

Cereno Scientific´s CEO Sten R. Sörensen will attend at the BIO-Europe 2018 Partnering Conference, which will take place in Copenhagen on 5-7 November.

“BIO-Europe is a very important conference that enables us to present Cereno Scientific and our drug candidate CS1 and at the same time establish contacts with representatives from most pharmaceutical companies with interests in thrombosis-related cardiovascular diseases,” says Cereno Scientifics CEO Sten R. Sörensen.

About BIO-Europe
BIO‐Europe is Europe's largest partnering conference for the global biotechnology industry. Participants from virtually all parts of the biotechnology value chain come to the conference to identify investment and collaboration opportunities and to establish strategic relationships. About 4,000 people from more than 2,100 companies are expected to attend this year's conference.

For more information, please contact:
Sten R. Sörensen – CEO

Tel: +46 733 74 03 74
E-mail sten.sorensen@cerenoscientific.com
www.cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558. 

About Us

Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-reducing properties, all relevant for PAH. A clinical Phase II study program for CS1 in PAH is expected to be initiated in mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.

Subscribe

Documents & Links